Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in patients with Birdshot HLA A29 uveitis: Phase II
2018-003653-16Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Feb 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of abatacept in birdshot chorioretinitis, sponsored by UZ Leuven. Primary endpoint: Time to recurrence of uveitis in ≥1 eye. Started Feb 2019; status: completed.
02
Drugs
abatacept
03
Conditions
birdshot chorioretinitis
Beyond the preview
Go deeper on 2018-003653-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003653-16.